Skip to Content
MilliporeSigma

59353-U

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 15 cm × 4.6 mm, HPLC Column

Synonym(s):

C8 Reversed-Phase Chromatography Column

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
15 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
C8 (octyl) phase
Pore size:
180 Å
Matrix:
silica gel, high purity, spherical base material, fully porous particle
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm

material

stainless steel column

Quality Level

agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range, 400 bar pressure (5801 psi)

technique(s)

HPLC: suitable, LC/MS: suitable

L × I.D.

15 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material, fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Application

Discovery® C8 HPLC column has been used in the separation of fluoroquinolone antibiotics in tablets using reversed-phase high-performance liquid chromatography (RP-HPLC).

Features and Benefits

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Explore all of our products under Discovery® C8 HPLC Column




Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Protocols

Separations of Tetracycline Antibiotics by Reversed Phase HPLC, Using Discovery Columns

Related Content

General Care and Use of Supelco™ HPLC Columns

Discovery C18 and C8 HPLC Columns products offered


Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of



Global Trade Item Number

SKUGTIN
59353-U04061838550194